Next Article in Journal
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Next Article in Special Issue
Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine
Previous Article in Journal
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
Previous Article in Special Issue
Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research
Open AccessReview

An Organotypic Microcosm for the Pancreatic Tumor Microenvironment

Department of Surgery, University of Kentucky, Lexington, KY 40536, USA
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 811;
Received: 28 February 2020 / Revised: 24 March 2020 / Accepted: 26 March 2020 / Published: 28 March 2020
(This article belongs to the Special Issue Cancer Organoids in Basic Science and Translational Medicine)
Pancreatic duct adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths in the next few years. Unfortunately, the development of novel therapies for PDAC has been challenged by a uniquely complex tumor microenvironment. The development of in vitro cancer organoids in recent years has demonstrated potential to increase therapies for patients with PDAC. Organoids have been established from PDAC murine and human tissues and they are representative of the primary tumor. Further, organoids have been shown beneficial in studies of molecular mechanisms and drug sensitivity testing. This review will cover the use of organoids to study PDAC development, invasiveness, and therapeutic resistance in the context of the tumor microenvironment, which is characterized by a dense desmoplastic reaction, hindered immune activity, and pro-tumor metabolic signaling. We describe investigations utilizing organoids to characterize the tumor microenvironment and also describe their limitations. Overall, organoids have great potential to serve as a versatile model of drug response and may be used to increase available therapies and improve survival for patients with PDAC. View Full-Text
Keywords: pancreatic cancer; organoids; tumor microenvironment pancreatic cancer; organoids; tumor microenvironment
Show Figures

Graphical abstract

MDPI and ACS Style

Lin, M.; Gao, M.; Pandalai, P.K.; Cavnar, M.J.; Kim, J. An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. Cancers 2020, 12, 811.

AMA Style

Lin M, Gao M, Pandalai PK, Cavnar MJ, Kim J. An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. Cancers. 2020; 12(4):811.

Chicago/Turabian Style

Lin, Miranda; Gao, Mei; Pandalai, Prakash K.; Cavnar, Michael J.; Kim, Joseph. 2020. "An Organotypic Microcosm for the Pancreatic Tumor Microenvironment" Cancers 12, no. 4: 811.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop